Aug 2013

Home >> Clinical Trials News Archive >> 2013 >> Aug 2013
Q-Trials have recently been granted an official international certification as a translations company compliant with the European standard EN 15038. Q-Trials' translations department consists of medical professionals, all well acquainted with the terminology and regulatory requirements of clinical trials. Q-Trials translate into Hebrew, English, Arabic and Russian, delivering top quality product within excellent timelines and competitive pricing.

MIT Technology Review cites Israel as leading Tech Hub . The July-August issue of MIT’s Technology Review noted Israel as one of 8 leading innovation clusters in the world. The others included Silicon Valley and Boston in the U.S., Skolkovo Innovation City (Russia), Bangalore (India), Beijing (China), Tech City (London), and Paris-Saclay (France).  Israel, which ranked in the top five, was particularly noted for its entrepreneurial culture and liberal immigration laws.

VentureBurn Magazine ranks Tel Aviv as top startup ecosystem. VentureBurn, the online magazine dedicated to the global venture capital community recently published a list of the top 20 startup ecosystems worldwide.  Israel placed # 2 just behind Silicon Valley and ahead of Los Angeles (#3), Seattle (#4), New York (#5), Boston (#6), Singapore (#17) and Bangalore (#19).  The authors explained Tel Aviv's high ranking, writing that “Given major acquisitions like the billion-dollar Waze, which sold recently to Google, clearly Israel’s second biggest city has got the gumption for start-ups.”

The FDA issued final guidance, "IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed." All of the parties who conduct or have oversight responsibilities for biomedical research—sponsors, clinical investigators, and institutional review boards (IRBs)—have responsibility for ensuring that the research complies with applicable laws and regulations and that risks to subjects are minimized.

FDA has issued Guidance for Industry on “Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring.” This guidance assists sponsors of clinical investigations in developing risk-based monitoring strategies and plans for investigational studies of medical products, including human drug and biological products, medical devices, and combinations thereof.

Philips healthcare announces plans to establish Israeli incubator. After meeting some 30 Israeli medical start-ups, senior VP for business development, strategy, and M&A at the Dutch multinational engineering and electronics conglomerate Philips Healthcare, Arnaud Bernaert, affirmed the company's conviction that it must expand the scope of its activity in Israel.

Germany's Bayer partners with Israeli Compugen on cancer therapy research. German pharmaceuticals company, Bayer AG, and Israeli drug company, Compugen Ltd., recently announced plans to collaborate on cancer treatment research, an agreement that could be worth some $500 million for Compugen. The agreement stipulates Bayer's application of the Israeli technology in its development of antibody-based immunotherapies. Immunotherapy is a medical treatment designed to stimulate the body's own immune cells to battle cancer.